Moreover, the 36-month beta value for GPCR is -3.74. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GPCR is 41.44M and currently, short sellers hold a 9.93% of that float. On April 26, 2024, GPCR’s average trading volume was 560.56K shares.
GPCR) stock’s latest price update
Structure Therapeutics Inc ADR (NASDAQ: GPCR)’s stock price has gone rise by 7.00 in comparison to its previous close of 36.43, however, the company has experienced a 7.74% increase in its stock price over the last five trading days. InvestorPlace reported 2024-04-24 that Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.
GPCR’s Market Performance
Structure Therapeutics Inc ADR (GPCR) has experienced a 7.74% rise in stock performance for the past week, with a -7.56% drop in the past month, and a -7.52% drop in the past quarter. The volatility ratio for the week is 5.52%, and the volatility levels for the past 30 days are at 5.51% for GPCR. The simple moving average for the past 20 days is -0.86% for GPCR’s stock, with a -10.69% simple moving average for the past 200 days.
Analysts’ Opinion of GPCR
Many brokerage firms have already submitted their reports for GPCR stocks, with Cantor Fitzgerald repeating the rating for GPCR by listing it as a “Overweight.” The predicted price for GPCR in the upcoming period, according to Cantor Fitzgerald is $65 based on the research report published on April 09, 2024 of the current year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see GPCR reach a price target of $90. The rating they have provided for GPCR stocks is “Mkt Outperform” according to the report published on October 19th, 2023.
Piper Sandler gave a rating of “Overweight” to GPCR, setting the target price at $58 in the report published on July 27th of the previous year.
GPCR Trading at -2.50% from the 50-Day Moving Average
After a stumble in the market that brought GPCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.04% of loss for the given period.
Volatility was left at 5.51%, however, over the last 30 days, the volatility rate increased by 5.52%, as shares sank -9.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.44% lower at present.
During the last 5 trading sessions, GPCR rose by +7.74%, which changed the moving average for the period of 200-days by +17.16% in comparison to the 20-day moving average, which settled at $39.12. In addition, Structure Therapeutics Inc ADR saw -4.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GPCR
The total capital return value is set at -0.23. Equity return is now at value -33.29, with -30.87 for asset returns.
Based on Structure Therapeutics Inc ADR (GPCR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -14.61. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -27.0.
Currently, EBITDA for the company is -101.74 million with net debt to EBITDA at 1.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.14.
Conclusion
To wrap up, the performance of Structure Therapeutics Inc ADR (GPCR) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
